Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H25FN2O2 |
| Molecular Weight | 416.4873 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC1=CC(=CC=C1[C@H]2CCN(C2)C(=O)C3=CC=C(F)C=N3)C4=CC=CC=C4C5CC5
InChI
InChIKey=NSHGEYJEPAJENJ-IBGZPJMESA-N
InChI=1S/C26H25FN2O2/c27-21-8-10-25(28-14-21)26(31)29-12-11-19(15-29)22-9-7-18(13-20(22)16-30)24-4-2-1-3-23(24)17-5-6-17/h1-4,7-10,13-14,17,19,30H,5-6,11-12,15-16H2/t19-/m0/s1
| Molecular Formula | C26H25FN2O2 |
| Molecular Weight | 416.4873 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 19:47:40 GMT 2025
by
admin
on
Wed Apr 02 19:47:40 GMT 2025
|
| Record UNII |
D5834H4GSQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
1018524
Created by
admin on Wed Apr 02 19:47:40 GMT 2025 , Edited by admin on Wed Apr 02 19:47:40 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2682864-35-1
Created by
admin on Wed Apr 02 19:47:40 GMT 2025 , Edited by admin on Wed Apr 02 19:47:40 GMT 2025
|
PRIMARY | |||
|
D5834H4GSQ
Created by
admin on Wed Apr 02 19:47:40 GMT 2025 , Edited by admin on Wed Apr 02 19:47:40 GMT 2025
|
PRIMARY | |||
|
156814747
Created by
admin on Wed Apr 02 19:47:40 GMT 2025 , Edited by admin on Wed Apr 02 19:47:40 GMT 2025
|
PRIMARY | |||
|
300000039878
Created by
admin on Wed Apr 02 19:47:40 GMT 2025 , Edited by admin on Wed Apr 02 19:47:40 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
under development for the treatment of itch associated with moderate to severe pruritus in patients with lichen simplex chronicus (LSC), type I punctate palmoplantar keratoderma or pachyonychia congenital, severe palmoplantar keratoderma (Olmsted) and ichthyoses (Harlequin ichthyosis).
|